



Published in final edited form as:

*Mol Oncol.* 2015 June ; 9(6): 1155–1168. doi:10.1016/j.molonc.2015.02.007.

## Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer

Jennifer L. Allensworth<sup>1,3</sup>, Myron K. Evans<sup>1,3</sup>, François Bertucci<sup>5</sup>, Amy J. Aldrich<sup>1</sup>, Richard A. Festa<sup>4</sup>, Pascal Finetti<sup>5</sup>, Naoto T. Ueno<sup>6</sup>, Rachid Safi<sup>3</sup>, Donald P. McDonnell<sup>2,4</sup>, Dennis J. Thiele<sup>4</sup>, Steven Van Laere<sup>7</sup>, and Gayathri R. Devi<sup>1,2,3</sup>

<sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC

<sup>2</sup>Duke Cancer Institute, Duke University Medical Center, Durham, NC

<sup>3</sup>Department of Pathology, Duke University Medical Center, Durham, NC

<sup>4</sup>Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC

<sup>5</sup>Department of Medical Oncology and Molecular Oncology, Institut Paoli-Calmettes, Marseille, France

<sup>6</sup>Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center

<sup>7</sup>Translational Cancer Research Unit, Oncology Center, General Hospital Sint-Augustinus, Antwerp, Wilrijk, Belgium

### Abstract

Cancer cells often have increased levels of reactive oxygen species (ROS); however, acquisition of redox adaptive mechanisms allows for evasion of ROS-mediated death. Inflammatory breast cancer (IBC) is a distinct, advanced BC subtype characterized by high rates of residual disease and recurrence despite advances in multimodality treatment. Using a cellular model of IBC, we identified an oxidative stress response (OSR) signature in surviving IBC cells after administration of an acute dose of an ROS inducer. Metagene analysis of patient samples revealed significantly higher OSR scores in IBC tumor samples compared to normal or non-IBC tissues, which may contribute to the poor response of IBC tumors to common treatment strategies, which often rely heavily on ROS induction. To combat this adaptation, we utilized a potent redox modulator, the FDA-approved small molecule Disulfiram (DSF), alone and in combination with copper. DSF forms a complex with copper (DSF-Cu) increasing intracellular copper concentration both *in vitro*

---

Corresponding Author: Gayathri Devi, Duke University, Box 2606, Durham, NC 27710. Phone: 919-668-0410; Fax: 919-681-7970; gayathri.devi@duke.edu.

#### CONFLICT OF INTEREST DISCLOSURE

The authors disclose no conflict of interest.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

and *in vivo*, bypassing the need for membrane transporters. DSF-Cu antagonized NF $\kappa$ B signaling, aldehyde dehydrogenase activity and antioxidant levels inducing oxidative stress-mediated apoptosis in multiple IBC cellular models. *In vivo*, DSF-Cu significantly inhibited tumor growth without significant toxicity, causing apoptosis only in tumor cells. These results indicate that IBC tumors are highly redox adapted, which may render them resistant to ROS-inducing therapies. DSF, through redox modulation, may be a useful approach to enhance chemo- and/or radio-sensitivity for advanced BC subtypes where therapeutic resistance is an impediment to durable responses to current standard of care.

## Keywords

apoptosis; SUM149; antioxidant; XIAP; NF $\kappa$ B; ALDH

## 1. INTRODUCTION

Oxidative stress is an imbalance between the levels of ROS within the cell and the antioxidant systems responsible for detoxifying ROS. Cancer cells are often characterized by increased levels of ROS due to metabolic and signaling aberrations (Gorrini et al., 2013); in order to compensate for high levels of ROS, cancer cells specially advanced subtypes survive by activating redox adaptive mechanisms including increased expression and activity of ROS-scavenging systems and antioxidants (Trachootham et al., 2009). Many anti-cancer regimens work at least in part through the generation of ROS, and thus may be rendered ineffective by redox adaptation. Chemotherapies including the anthracyclines (doxorubicin), taxanes (paclitaxel, docetaxel), alkylating agents, and platinum compounds (cisplatin, carboplatin) as well as radiation therapy all rely heavily on the induction of oxidative stress-induced apoptosis for their anti-tumor activities (Brown and Bicknell, 2001; Manda et al., 2009; Trachootham et al., 2009); thus, redox adaptation can confer resistance to many breast cancer therapies.

Inflammatory breast cancer (IBC) is one of the most aggressive forms of disease that presents with a unique pathobiology in which hyperproliferative clusters, or tumor emboli, are formed (Robertson et al., 2010). Due to its high metastatic potential and frequent occurrence of therapeutic resistance, the prognosis remains poor with a 3-year survival of ~40% despite progress in multimodality treatment (Masuda et al., 2014). Following trimodal therapy including neoadjuvant chemotherapy (CT), surgery, and post-operative radiation, patients with IBC are more likely to have residual disease and have a significantly higher risk of recurrence (Rueth et al., 2014; Saigal et al., 2013). Both residual disease and recurrence following what appears to have been clearance of the tumor are a direct result of resistant cells that are able to survive these anticancer therapies. Clearly, therapeutic resistance is a serious problem for the IBC population, and new molecular therapeutic targets need to be identified to improve treatment and increase patient survival. Further, IBC can serve as a model for studying the role of cellular oxidative stress responses in modulating the efficacy of anti-cancer therapies.

Gene expression analyses show that IBC tumors have elevated expression of the redox-sensitive nuclear transcription factor NF $\kappa$ B, and related survival signaling pathways

compared to non-IBC tumors (Iwamoto et al., 2011; Nguyen et al., 2006; Van Laere et al., 2006). Pre-clinical evidence in cellular models of IBC indicates that redox adaptation through enhancement of cellular antioxidant capacity can confer therapeutic resistance to a number of drugs including classical ROS inducers, chemotherapeutics, and targeted agents (Aird et al., 2012; Allensworth et al., 2012; Williams et al., 2013). We hypothesize that redox adaptation via enhancement of the oxidative stress response plays a significant role in therapeutic resistance in the IBC patient population; thus, to overcome resistance, induction of ROS must be accompanied by rational targeting of those adaptive mechanisms.

Disulfiram (DSF), a member of the dithiocarbamate family, is an FDA-approved drug for alcoholism which can react with redox-sensitive sulfhydryl groups (thiols) and bind copper (Cu) (Hogarth, 2012), an essential cofactor for the key cellular enzymes (e.g. cytochrome c oxidase and superoxide dismutase 1 (SOD1)) involved in oxidative stress response (Fraga, 2005). Notably, DSF is a redox modulator whose induction of ROS is enhanced by the addition of Cu (Yip et al., 2011), and it has been reported to inhibit the activity of NF $\kappa$ B (Wang et al., 2003; Yip et al., 2011), a potential mediator of redox adaptation in IBC. These properties highlight DSF as an attractive agent by which to enhance cancer cell death and enhance therapeutic sensitivity in IBC.

We analyzed a cohort of IBC and non-IBC pre-treatment biopsies using an oxidative stress response (OSR) metagene generated by analyzing the genes activated and repressed in IBC cells in culture that mount a successful protective response to an ROS inducer. Consistent with our hypothesis, IBC patient samples exhibited significantly higher OSR scores, indicating an enhancement of protective mechanisms that enables them to survive an onslaught of ROS, i.e. redox adaptation. We then conducted a number of mechanistic studies in both cellular and animal models of IBC to assess the strategy of targeting redox adaptation with DSF alone and in combination with Cu. Our study provides strong evidence that DSF, in conjunction with Cu, targets tumor redox adaptation to reverse therapeutic resistance and supports the use of DSF as a novel anti-cancer drug in IBC.

## 2. MATERIALS AND METHODS

### 2.1 Gene expression profiling of H<sub>2</sub>O<sub>2</sub>-treated SUM149 cell lines and clinical samples

Messenger RNA triplicates of SUM149 cells treated with or without H<sub>2</sub>O<sub>2</sub> were profiled using the Affymetrix HGU133A2 GeneChip at Duke University Institute for Genome Sciences and Policy Microarray Facility. Raw expression data were background-corrected, normalized, and summarized using Robust Multiarray Averaging method taking into account probe sequence information (GCRMA). Normalized data were filtered to include only probe sets that showed expression above log<sub>2</sub>(100) in at least 2/6 expression profiles, resulting in 9,962 informative data points. Differential gene expression analysis between treated and untreated cells was performed using linear regression models implemented in the limma package of BioConductor in R. P-values were corrected for false discovery rate (FDR) using the Benjamini and Hochberg correction. Probe sets were considered significant if the nominal p-value was smaller than 0.05, the FDR-adjusted P-values smaller than 0.1, and the fold change (ratio SUM149 cells H<sub>2</sub>O<sub>2</sub>-treated versus untreated) higher than |2|. A metagene signature designated “oxidative stress response” (OSR) was generated from the

resulting gene list and defined for each sample as follows: ratio between average expression level of genes upregulated and average expression level of genes downregulated in H<sub>2</sub>O<sub>2</sub>-treated cells. This classifier was applied to a series of 389 pre-treatment IBC and non-IBC samples previously described (Bertucci et al., 2013; Van Laere et al., 2013). Those samples were obtained from pre-treatment biopsies from patients treated in three institutions: Institut Paoli-Calmettes (IPC, Marseille, France: 71 IBC and 139 non-IBC), MD Anderson Cancer Center (MDA, Houston, TX, USA: 25 IBC and 58 non-IBC), and General Hospital Sint-Augustinus (TCRU, Antwerp, Belgium: 41 IBC and 55 non-IBC). Patients with IBC were selected by strictly adhering to the consensus diagnostic criteria published by Dawood and colleagues (Dawood and Cristofanilli, 2011). Each patient gave written informed consent, and this study was approved by the institutional review boards of all 3 participating centers. The normal breast samples series contained 21 samples extracted from the GEO public database (GSE31448, GSE16873, GSE21422). Before applying the metagene signature, Empirical Bayes normalization method with inSilicoMerging package (Taminau et al., 2012) was applied to merge all expression data sets and remove inter-study bias; correct normalization was checked using PCA (data not shown). The molecular subtype of tumors was based on the ER, PR and HER2 statuses (Bertucci et al., 2013; Van Laere et al., 2013) as follows: hormone receptor (HR)+/HER2- for ER and/or PR+ and HER2- samples, HER2+ for HER2+ samples, and triple negative (TN) for ER-/PR-/HER2- samples. A metagene score was calculated based upon the genes common to the signature and all data sets after background filtering. In addition, we tested the relationship between the IBC/non-IBC phenotype from our 389-sample series and another “oxidative stress” expression signature represented by the 84-gene list from the Human Oxidative Stress RT2 Profiler PCR Array (Qiagen). Fifty-five out of 84 genes were present in our data set and retained after background filtering, and used to classify the 389 samples by unsupervised analysis (Principal Component Analysis, PCA). We then defined the “Qiagen oxidative stress” metagene as the first component of PCA and compared its distribution between IBC and non-IBC.

## 2.2 Cell culture

SUM149 and SUM190 cells were obtained from Asterand, Inc. and cultured as described previously (Aird et al., 2008). Asterand routinely characterizes cell lines by short tandem repeat polymorphism analysis. Cells were banked upon receipt and cultured for no more than 6 months before use in any assay. rSUM149 and rSUM190 are isogenic acquired resistance models established in the laboratory (Aird et al., 2010). MDA-IBC-3 cells were kindly provided by Dr. Woodward (MD Anderson Cancer Center) and cultured as described (Klopp et al., 2010).

## 2.3 Trypan blue viability assay

Cells were treated for 24 h in regular growth medium with Disulfiram (Sigma), CuSO<sub>4</sub> (VWR), SOD mimetic (MnTnHex-2-PyP<sup>5+</sup>), bathocuproine disulfonate (BCS, Sigma), and tetrathiomolybdate (TM, Sigma). Cell viability was determined by trypan blue exclusion as described previously (Aird et al., 2008) where % viability was calculated as live cells/total cells × 100.

## 2.4 Western immunoblotting

Cell lysates were harvested after treatment with DSF  $\pm$  Cu for 24 h. Membranes were incubated with primary antibodies against XIAP, SOD2 (BD Bioscience), SOD1, PARP, eIF4G1, p38, ERK1/2 (p44/42 MAPK), NF $\kappa$ B (p65 subunit) (Cell Signaling Technologies), Ctr1 (Nose et al., 2006), actin, or GAPDH (Santa Cruz Biotechnology Inc.) overnight at 4°C as described previously (Aird et al., 2008). Additional information about antibodies used in this study is provided in Supplementary Table 1. Stripping of membranes to detect total protein was done as previously (Aird et al., 2010). Densitometric analysis was conducted using NIH ImageJ software (Abramoff, 2004).

## 2.5 Measurement of ROS

Mitochondrial (MitoSox Red) and cytoplasmic (DHE) ROS were measured as described previously (Aird et al., 2012). Cells were treated with DSF  $\pm$  Cu for 24 h, harvested, and analyzed by flow cytometry. 25,000 events were collected on a FACSCalibur (Becton Dickinson) flow cytometer and analyzed using Cellquest (Becton Dickinson). For DHE, high fluorescence was calculated by setting a gate on control cells where the peak reached a minimum; experimental samples were compared to this control.

## 2.6 Glutathione assay

Reduced glutathione levels were assessed as described previously (Aird et al., 2012) using the GSH-Glo Glutathione Assay (Promega) according to manufacturer's instructions.

## 2.7 Nrf2 activity assay

Cells in opaque 96-well plates (Greiner Bio-One) were transfected with pGL4.37 (ARE firefly luciferase reporter, Promega) and pGL4.75 (Renilla luciferase control, Promega) plasmids using a 3:1 ratio of Xtremegene HP (Roche Applied Science, Indianapolis, IN) to DNA. The next day, cells were treated with as indicated. After 24 h, the Dual-Glo Luciferase Assay System (Promega) was used and luminescence read on a Veritas microplate luminometer (Turner BioSystems). Firefly luminescence was normalized to Renilla luminescence for each sample, and this value normalized to untreated.

## 2.8 Measurement of cell-associated Cu in cell lysates and murine tumor tissue

Cell lysates were prepared as above. For tumors, a portion of each tumor was placed into tissue lysis buffer (GoldBio Technology) and homogenized using the Bullet Blender Storm and lysis beads (MidSci). Lysates were analyzed for Cu content using a Thermo Scientific Element2 inductively coupled plasma high-resolution mass spectrometer (ICP-HRMS) at the W.M. Keck Elemental Geochemistry Laboratory (University of Michigan, Ann Arbor, MI), and Cu content of lysis buffer blank was subtracted from each sample. Values were normalized to protein for reporting as ng Cu/mg protein.

## 2.9 Ctr1 knockdown

A luciferase-targeting control or Ctr1-targeting siRNAs (A and B, Invitrogen) were transfected into cells using Dharmafect 1 reagent (Thermo Scientific). 24 h post-

transfection, DSF, Cu, or DSF-Cu was added and cells were harvested for trypan blue staining and western immunoblotting to confirm knockdown after 24 h.

### 2.10 Complementation of *Saccharomyces cerevisiae* Cu<sup>+</sup>-transport mutants

SEY6210 (wild type) (Robinson et al., 1988) and *ctr1/ctr3* mutant MPY17 *S. cerevisiae* cells (Pena et al., 1998) were grown in YPEG media (3% ethanol, 3% glycerol, 1% yeast extract, 2% Bacto Peptone, 2% agar) with addition of 0-50  $\mu$ M known Cu ionophore, zinc pyrithione (ZPT) (Reeder et al., 2011), or DSF. Cells were allowed to grow at 30°C for 3 days; growth was assessed by measuring optical density at 600nm on a Spectramax Plus 384 plate reader (Molecular Devices).

### 2.11 ALDEFLUOR assay

ALDH enzymatic activity was assessed using the ALDEFLUOR kit (Stem Cell Technologies) according to the manufacturer's instructions. Briefly, cells were incubated with ALDH substrate for 35 minutes at 37°C. The specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) was used as negative control. Sorting gates were established using 7-AAD stained cells for viability and ALDEFLUOR-stained cells treated with DEAB as negative controls. Dot plots from a representative experiment are shown with mean  $\pm$  SEM from four experiments.

### 2.12 Mammosphere growth

Matrigel was applied to 24-well plates at 150  $\mu$ L/cm<sup>2</sup> and incubated at 37°C for 30 min to allow gel to solidify, after which 25,000 cells were seeded. After overnight incubation, treatments were applied for 24 h; images were recorded using a Motic AE2000 microscope, M14 camera, and Infinity Capture (Lumenera) software.

### 2.13 Anchorage-independent growth assay

AIG was measured as previously described (Allensworth et al., 2013). Images of representative fields were taken with 5x magnification using a Zeiss Axio Observer microscope, Hamamatsu Orca ER digital camera, and MetaMorph software (Molecular Devices).

### 2.14 Human breast tumor xenograft studies

Female SCID mice were obtained from a breeding colony at the Cancer Center Isolation Facility at Duke University. All experiments were performed in accordance with the Duke University International Animal Care and Use Committee. SUM149 cells ( $1 \times 10^6$ ) were suspended in 50  $\mu$ L PBS/50  $\mu$ L Matrigel and injected into the flank subcutaneously. Once tumors were palpable (50-60 mm<sup>3</sup> volume or approximately 4.5-5mm length or width), mice were randomly assigned to treatment groups: vehicle control (V= 5% DMSO, 5% EtOH, 90% corn oil), DSF (50 mg/kg in V), or combination of DSF in V and Cu (0.5 mg/kg) in saline (n=5-6). Animals were treated daily via intraperitoneal injection, and tumor volume measured using the formula  $V = (L \times W^2)/2$  where *L* is length and *W* is width of the tumor. Tumor growth inhibition was calculated using the formula:  $TGI = (1 - (T/V)) * 100$ , where *T* is mean tumor volume for DSF-Cu or DSF and *V* is mean tumor volume for vehicle. When

control tumors reached humane endpoint, the experiment was terminated and all mice were sacrificed. Tumors were removed, and tissue was harvested for H&E staining, TUNEL assay, western immunoblotting, and Cu measurement.

### 2.15 TUNEL staining of murine tumor tissue

Tumor xenografts were fixed in 10% formalin, processed and embedded in paraffin. Serial sections were cut and deparaffinized in a series of 100%, 95% and 70% ethanol for 5 min each and washed in 1X PBS. Sections were incubated with 20 µg/mL Proteinase K solution (Roche Diagnostics) for 15 min at 25°C. After 2 washes in 1X PBS, sections were incubated with In Situ cell death enzyme as per manufacturer's instructions (In Situ Cell Death Detection Kit, Roche). Sections were coverslipped and mounted with Prolong Anti-fade mounting medium with DAPI (Invitrogen), imaged using the Zeiss Axio Imager microscope, and analyzed with Metamorph and ImageJ software.

### 2.16 Statistical analysis

The statistical analyses were conducted using GraphPad Prism (GraphPad Software, Inc.) Student's 2-tailed t-test and Fisher's exact test. Differences were considered significant at  $p < 0.05$ .

## 3. RESULTS

### 3.1 Altered oxidative stress response in IBC versus non-IBC clinical samples

We first defined an oxidative stress response (OSR) signature by performing a supervised analysis comparing expression profiles of untreated SUM149 cells with SUM149 cells challenged with an acute 1h exposure to 500 µM H<sub>2</sub>O<sub>2</sub>. Following H<sub>2</sub>O<sub>2</sub> exposure, the cells were allowed to recover for 24h, and then the OSR response was analyzed in the surviving tumor cells. We identified 642 differentially expressed probe sets representing 532 genes, 248 genes upregulated and 284 downregulated, in response to H<sub>2</sub>O<sub>2</sub> challenge and recovery (Figure 1A). A metagene set designated "oxidative stress response" (OSR) was generated from this gene list (521 out of 532 genes retained after filtering), with genes upregulated including NFκB targets, antioxidants, heat shock proteins, DNA damage repair systems, and many others previously validated as participants in the oxidative stress response (Supplemental Table 2).

In order to investigate our hypothesis that IBC tumors are inherently more resistant to ROS-mediated cancer therapies as a result of an enhanced oxidative stress response, we applied the OSR metagene to gene expression data from 137 IBC patients and 252 non-IBC patients treated across three centers as well as 21 normal breast samples. All BC samples were from diagnostic biopsies taken before systemic therapeutic intervention. As shown in Figure 1B, OSR metagene values were higher in BC patient tissues (both IBC and non-IBC) than in normal breast samples ( $p=2.35E-06$  for IBC vs normal), and IBC samples exhibited significantly higher OSR values than non-IBC samples ( $p=1.54E-04$ ). Figure 1C shows an enrichment of IBC tumors among the BC samples that display a higher metagene value and conversely, an enrichment of non-IBC tumors among the breast cancer samples that display a lower value ( $p=3E-03$ ; Fisher's exact test). Figure 1D shows the heatmap built from the 40

most differentially expressed genes out of 521. Per molecular subtype, we found that the OSR metagene was significantly higher in IBC than in nIBC in the HR+/HER2- subtype ( $p=0.026$ ) and the HER2+ subtype ( $p=9.7E-04$ ), whereas there was no significant difference in the TN subtype ( $p=0.23$ ) (data not shown). In order to validate the findings of our OSR metagene, we compared the distribution of values between IBC and non-IBC in a metagene set from Qiagen, which includes 55 genes that are known to regulate oxidative stress response in multiple cell types. Here again, IBC showed significantly higher metagene values than non-IBC ( $p=0.01$ ; Student's t-test; data not shown), indicating that the pronounced activation of the oxidative stress response observed with the 521-gene signature does not depend on the fact that this signature was identified in a preclinical model of IBC. Together, these results support a general enhancement of the oxidative stress response in BC cells compared to their normal counterparts, indicative of redox adaptation. Within BC, IBC tumors are characterized by an especially strong activation of this protective regimen, which may contribute to therapeutic resistance, residual disease, and high rate of recurrence following treatment. Therefore, advanced breast cancer like IBC is likely to benefit significantly from the addition of a redox modulatory therapy that targets mediators of the oxidative stress response.

### 3.2 A novel redox modulatory strategy (DSF-Cu) overcomes the OSR in therapy-resistant IBC cells

Having determined that the oxidative stress response is especially strong in IBC patient samples, we next sought to discern whether targeting this system could enhance ROS-induced therapeutic cell death in these aggressive tumors. For this purpose we selected DSF, a redox modulator that can react with protein thiols, bind Cu, and has been reported to inhibit NF $\kappa$ B. We characterized the effects of DSF alone and in combination with exogenous Cu on ROS generation and downstream redox signaling in therapy-resistant, redox-adapted rSUM149 cells [isogenic clonal derivatives (Aird et al., 2010) of well-established, triple-negative SUM149 IBC cell line show increased tolerance to ROS-inducing agents ( $H_2O_2$ , paraquat), kinase inhibitors (lapatinib, sorafenib, sunitinib, gefitinib) and chemotherapies (including taxanes, vinca alkaloids, capecitabine, mitoxantrone, mitomycin C, and anti-aromatases) (Williams et al., 2013). Data in Figure 2A show that DSF-Cu induced significant levels [comparable to levels in SUM149 cells exposed to ROS-inducing agents (Aird et al., 2012; Evans et al., 2013)] of mitochondrial (white bars) and cytoplasmic (black bars) superoxide radicals compared to DSF or Cu alone. Increased ROS corresponded with decreased superoxide dismutase 1 (SOD1) expression (Fig. 2B) and decreased levels of GSH (rSUM149 shown), the most potent cellular ROS scavenging system (Fig. 2C). We then investigated the effects of DSF-Cu on activity of Nrf2 and NF $\kappa$ B redox-responsive transcription factors (Bellezza et al., 2010). Figure 2D shows that Cu (10  $\mu$ M) and high-dose DSF (10-20  $\mu$ M) induced Nrf2 transcriptional activity; however, the strongest induction was observed with low dose DSF-Cu (150 nM, 10  $\mu$ M). DSF-Cu decreased NF $\kappa$ B phosphorylation within 4 h following treatment (Fig. 2E), and this reduction was sustained 24 h post-treatment (Suppl. Fig. S1). The ROS increase also corresponded with increased phosphorylation of p38 MAPK and ERK1/2 (Fig. 2E). Incubation of cells with an exogenous SOD mimetic (MnTnHexyl-2-PyP<sup>5+</sup>) with potent antioxidant activity blocked cell death caused by DSF-Cu treatment (Fig. 2F, gray bars,



rSUM149 shown), confirming the pro-oxidant role of DSF-Cu in inducing cell death in redox-adapted rSUM149 cells.

### 3.3 DSF-Cu induces cell death corresponding with XIAP and eIF4G1 downregulation

We next sought to compare the effect of DSF and DSF-Cu on viability of multiple BC cell lines. DSF induced cell death only at higher micromolar concentrations (Fig 3A: SUM149- left, squares,  $IC_{50} \sim 17 \mu\text{M}$ ; rSUM149- right, squares,  $IC_{50} \sim 25\text{-}30 \mu\text{M}$ ), and Cu alone was not cytotoxic. DSF's potency was significantly enhanced by addition of  $10 \mu\text{M}$  Cu (DSF-Cu), with approximately 100-fold decrease in  $IC_{50}$  values in SUM149 and rSUM149. Remarkably, DSF-Cu caused cell death in redox-adapted rSUM149 cells at levels comparable to parental redox-sensitive SUM149 cells. DSF-Cu has been found to be non-toxic to normal, immortalized breast cells (MCF10A) at up to  $20 \mu\text{M}$  (Chen et al., 2006). In addition, similar to SUM149 cells, DSF-induced cell death by Cu was observed in other IBC cell lines tested (Suppl. Fig. S2), which included MDA-IBC-3 (Her2-overexpressing), SUM190 (Her2-overexpressing, ROS sensitive), and rSUM190 (isogenic derivative of SUM190 with therapeutic resistance, redox adaptation). SUM190 cells were highly sensitive to DSF-Cu treatment even at very low DSF concentrations. Comparison with other non-IBC cell lines (T47D, MDA-MB-436, and MDA-MB-468) revealed that similar to IBC cells, addition of Cu to DSF induced cell death at similar dose ranges tested, albeit with somewhat lower potency compared to SUM149 cells (data not shown).

Decrease in IBC cell viability in the presence of DSF-Cu correlated with decreased levels of XIAP, considered the most potent mammalian caspase inhibitor and anti-apoptotic protein (Fig. 3B). This is consistent with the fact that oxidative stress can trigger the intrinsic apoptotic pathway, and our previous studies identified that XIAP overexpression in IBC cells correlates with resistance to therapeutic apoptosis (Aird et al., 2008; Aird et al., 2010; Allensworth et al., 2012). Further, DSF-Cu-mediated cell death was associated with decreased expression of eIF4G1 (a disease progression factor identified in IBC tumors (Silvera et al., 2009)) and increased PARP cleavage (Fig. 3B). Together, these data suggest that induction of apoptotic cell death is a primary mode of action of DSF-Cu.

To determine whether the interaction between DSF and Cu is necessary for DSF's mechanism of action, we evaluated the impact of disrupting the DSF-Cu interaction using high affinity chelators to sequester free Cu. Addition of bathocuproine disulphonate (BCS, white bars) (Cen et al., 2004), or tetrathiomolybdate (TM, gray bars) (Brewer, 2009) almost completely blocked DSF-Cu-induced cell death (black bars) SUM149 (Fig. 3C, left) and rSUM149 (Fig. 3C, right) cells, highlighting the importance of Cu binding for enhancement of DSF's cytotoxic effects. While TM has been previously reported to induce cancer cell death through its ability to sequester Cu (Brewer, 2009), the TM-Cu mixture was without effect in these models of IBC. These data confirm that the activity of DSF is not related to Cu sequestration, but rather a gain of function that results in increased ROS production.

### 3.4 DSF is a Cu ionophore that induces Ctr1-independent Cu accumulation in IBC cells

Given that Cu interacts with DSF and this interaction is necessary for cytotoxicity, it was of interest to address whether DSF affects Cu accumulation in IBC cells. A slight increase in

Cu accumulation at 24 h, measured by ICP-HRMS, was observed upon treatment with 10  $\mu$ M Cu; however, there was a dramatic dose-dependent increase in cell-associated Cu following treatment with DSF-Cu, with up to a 30-fold increase at the maximum concentration tested (Fig. 4A). Analysis of protein levels of the Cu transporter Ctr1, which tightly regulates Cu import, revealed expression (Fig. 4B) in mammary epithelial cells (HME1), normal-like MCF10A cells, and the IBC cell lines (SUM149, rSUM149, SUM190, MDA-IBC-3). rSUM149 cells expressed Ctr1 at much lower levels than SUM149, but notably, Cu accumulation in the presence of DSF (Fig. 4A) was similar in SUM149 and rSUM149 cells irrespective of Ctr1 expression status. These findings suggest that transport via the classical cellular Ctr1 mechanism may not play a significant role in DSF-mediated Cu accumulation. To investigate the possibility that DSF may promote cellular uptake of Cu in a Ctr1-independent fashion, two Ctr1-targeting siRNAs were used to knock down expression of the Cu transporter in SUM149 cells (Fig. 4C, right). Assessment of viability revealed that Ctr1 knockdown (Fig. 4C, left, black and gray bars) does not change the sensitivity of SUM149 cells to DSF (Fig. 4C, left, white bars).

In addition, to further evaluate the Cu ionophore activity of DSF, we took advantage of a novel yeast model. We examined the growth of wild type *S. cerevisiae* (SEY6210) and a *ctr1/ctr3* mutant (MPY17) lacking both high affinity Cu transporters (yeast express Ctr1 and Ctr3, while humans have only Ctr1) (Pena et al., 1998) in YPEG media, where Cu is required for growth. Data in Figure 4D show that while wild type SEY6210 cells (white bars) grew well in YPEG due to their ability to take up trace levels of Cu from the media, the *ctr1/ctr3* MPY17 cells (black bars) did not. However, in the presence of the known Cu ionophore zinc pyrithione (ZPT) (Reeder et al., 2011), MPY17 cells grew similarly to the SEY6210 cells. In this assay, the addition of DSF to MPY17 cells enhanced their growth similar to ZPT treatment. These results strongly support that DSF acts as a Cu ionophore in a Ctr1-independent manner leading to DSF-Cu mediated cell death in IBC cells.

### 3.5 DSF-Cu inhibits anchorage-independent growth and ALDH1 activity in IBC cells

Because SUM149 cells can form mammospheres (Debeb et al., 2012) and therapeutic response of 3D cultures is generally more indicative of *in vivo* activity, the effects of DSF, Cu, and DSF-Cu on 3D IBC structure were assessed. We observed ablation of IBC cell mammospheres formed in Matrigel after treatment with DSF-Cu, evidenced by dispersion of cell clusters (Fig. 5A). Paralleling 2D culture conditions, SUM149 mammospheres remained intact following treatment with either agent alone.

Anchorage-independent growth (AIG) in soft agar is widely used as an *in vitro* model to assess cancer cell tumorigenicity and is considered a useful predictor of *in vivo* activity (Debeb et al., 2012). AIG (measured by colony number) was significantly inhibited by DSF-Cu in both SUM149 and rSUM149 cell lines (Fig. 5B). Representative images in Figure 5C show an abundance of large colonies in untreated and single treatment samples, while only diffuse individual cells are seen in DSF-Cu-treated samples.

Since DSF is an inhibitor of the aldehyde dehydrogenase class of enzymes (Johansson, 1992), we wanted to determine whether DSF or DSF-Cu could inhibit the tumorigenic factor ALDH. SUM149 cells were treated for 24 h with a sub-lethal dose of DSF or DSF-Cu and

analyzed for ALDH activity using the ALDEFLUOR assay. Data in Figure 5D show that while neither DSF nor Cu alone affected the ALDH<sup>+</sup> population, DSF-Cu significantly reduced the proportion of ALDH<sup>+</sup> cells (Fig. 5D,  $p < 0.005$ ). These data are highly relevant as IBC tumors and cell lines, including SUM149, are often characterized by a high degree of ALDH activity, which has been linked with increased growth capacity in 3D culture and enhanced tumorigenicity *in vivo* (Charafe-Jauffret et al., 2010).

### 3.6 DSF-Cu inhibits growth of SUM149-derived tumors in an *in vivo* murine model

To further investigate DSF as a potential therapeutic strategy for IBC, we utilized an *in vivo* tumor model to evaluate the anti-tumoral efficacy of systemically administered DSF and Cu. Mice were treated daily with vehicle control, DSF, or DSF-Cu, and tumor volume was monitored. DSF-Cu significantly inhibited growth of SUM149 tumors compared to vehicle control and DSF alone ( $p = 3.4E-06$ , Fig. 6A). Mice treated with DSF-Cu reached an average tumor volume of 363 mm<sup>3</sup> over the study, while all vehicle-treated tumors exceeded 1500 mm<sup>3</sup>, revealing ~84% inhibition of tumor growth (Fig. 6A). Tumor burden in the DSF treatment group was reduced at the time of dissection despite no reduction in tumor growth, however tumor burden was lowest in the DSF-Cu group (~75%;  $p < 0.0001$ ). Whole animal weights did not change significantly in any group during treatment (Suppl. Table 3). Data in Figure 6B show reduced levels of NF $\kappa$ B p65 phosphorylation, eIF4G1 and SOD1 expression in DSF-Cu-treated tumor lysates, consistent with results from our *in vitro* studies (Fig. 2B, 3B). Tumors from mice treated with vehicle and DSF showed little to no TUNEL staining (apoptotic marker) (Fig. 6C, left and middle panel), while tumor cells from DSF-Cu-treated mice showed significant TUNEL staining (Fig. 6C, right panel). Quantitation of the number of TUNEL positive cells is displayed in Figure 6D.

Our own studies (Fig. 4), consistent with a previous report (Cen et al., 2004), indicated that DSF can increase uptake of Cu by cancer cells in culture. Because bioavailability and tissue distribution are important pharmacokinetic factors, we investigated whether administered Cu reached the tumor by comparing Cu concentrations between treated tumors. DSF-Cu treatment resulted in higher intratumoral Cu concentrations measured via ICP-HRMS, although the difference was not statistically significant potentially due to limited sample size (Fig. 6E). Together, these results indicate that DSF-Cu is an effective combination whose mechanisms including targeting of the oxidative stress response and the anti-apoptotic program work together to inhibit tumor growth in an *in vivo* setting. The schematic in Figure 6F summarizes the multi-factorial mechanisms that contribute to DSF-Cu's anti-tumoral efficacy.

## 4. DISCUSSION

Cancer cells are under persistent oxidative stress relative to normal cells, and redox status regulates many cancer cell characteristics such as activation of proto-oncogenes and transcription factors, genomic instability, and therapeutic outcome. To compensate for increased oxidative stress, cancer cells activate redox adaptive mechanisms which enhance their ability to detoxify ROS (Trachootham et al., 2009). To examine oxidative stress response in BC, we identified 521 differentially expressed genes in SUM149 cells (an established, well-studied model of IBC) with and without addition of the classical ROS

inducer, H<sub>2</sub>O<sub>2</sub>. We applied this oxidative stress response (OSR) metagene to expression data from pretreatment IBC and non-IBC clinical samples and normal breast tissue. The data revealed the identified OSR metagene scores were significantly higher in IBC samples than in non-IBC samples or normal breast tissue. As the efficacy of many anti-cancer agents depends on a strong induction of ROS and oxidative stress-induced cell death, resistance to those therapies develops when cancer types with inherently high ROS levels like IBC evolve redox adaptive mechanisms that allow them to survive in an environment of increased oxidative stress. Thus, the IBC tumor cells with an inherently high OSR may represent a redox-adapted population that develops high rates of failure to ROS-inducing treatments like chemo- and radiotherapy. Therefore, introduction of a redox modulatory strategy has the potential to block the oxidative stress response, tip the balance toward ROS-mediated cell death, and enhance efficacy of traditional therapies in cancer cells (Trachootham et al., 2009). In the current study, DSF, an FDA-approved anti-alcoholism drug used for over 40 years with extensive pre-clinical, clinical, and safety data (Johansson, 1992), induced potent ROS accumulation and death in IBC cells when combined with exogenous Cu. Further, DSF-Cu equalized the response of cells with acquired therapeutic resistance (rSUM149 and rSUM190) to that of their more sensitive parental counterparts.

In addition to the fact that dithiocarbamates like DSF can bind Cu (Hogarth, 2012), we identified that DSF acts as a Cu ionophore, facilitating cellular Cu accumulation in a Ctr1-independent manner. Although use of Cu as an anti-cancer agent is considered attractive (Gupte and Mumper, 2009), intracellular transport of Cu is a major challenge due to stringent control by Cu transporters. One scenario for the mechanism of DSF-Cu complex formation is that lipophilic DSF penetrates into cancer cells to form the apoptosis-inducing Cu(deDTC)<sub>2</sub> complex with intracellular Cu. As many cancer cells, including breast, have higher levels of Cu than normal tissue (two- to three-fold increases) (Mulay et al., 1971; Rizk and Sky-Peck, 1984), the increase in Cu(deDTC)<sub>2</sub> after DSF enters may enable DSF to target cancer cells selectively (Chen et al., 2006). However, in the IBC cells tested here, DSF induced toxicity only at concentrations greater than 10 μM, a dose that is not readily achievable in human plasma where the accepted daily dosing of 250-500 mg yields a plasma concentration <2 μM (Faiman et al., 1984). DSF's potency was significantly enhanced by exogenous Cu, with IC<sub>50</sub>s for DSF-Cu in the 200-300 nM range in SUM149 and rSUM149 (Fig. 3A). In the present study, the addition of DSF significantly enhanced cell-associated Cu concentrations (Fig. 4A), indicating that DSF plays a role in mediating Cu uptake rather than just binding intracellular Cu. Further, the fact that DSF-Cu is equally effective in rSUM149 cells, which express Ctr1 at significantly lower levels than SUM149 (Fig. 4B), indicates that a Ctr1-independent mechanism is behind DSF-Cu efficacy. The inability of Ctr1 knockdown to inhibit DSF-Cu-mediated cell death (Fig. 4C) confirms the Ctr1-independence of DSF-Cu and provides further evidence for DSF as a Cu ionophore. These results are consistent with a model in which DSF complexes with Cu in the extracellular space and transports it across the plasma membrane into the cell as part of the Cu(deDTC)<sub>2</sub> complex.

It has been shown that dysregulation of NFκB (a pro-survival factor and redox sensor) and its target genes is a critical molecular determinant in IBC disease progression (Iwamoto et al., 2011; Nguyen et al., 2006; Van Laere et al., 2006). DSF-Cu inhibited NFκB activation

and decreased antioxidants levels in SUM149 and rSUM149 cells, leading to activation of a pro-apoptotic redox response (Fig. 2B, C, and E). Another observation of significance is downregulation of XIAP by DSF-Cu (Fig. 3B). XIAP, the most potent anti-apoptotic protein, is considered a chemoresistance factor in many cancer types (Kashkar, 2010), and we have previously reported a strong correlation between XIAP overexpression and acquired resistance to trastuzumab (Aird et al., 2008), TRAIL (Allensworth et al., 2012), lapatinib (Aird et al., 2010), and other therapies (Williams et al., 2013) in IBC. Further, XIAP is a Cu homeostasis factor, and formation of a Cu-XIAP complex can inhibit XIAP's anti-apoptotic function (Mufti et al., 2007), identifying a potential mechanism by which DSF-Cu induces apoptosis. Inhibition of NF $\kappa$ B, a positive transcriptional regulator of XIAP, may also play a role in XIAP's downregulation. Further, XIAP is translationally upregulated during cell stress, which may involve the translation initiation factor eIF4G1 (Silvera et al., 2009). As eIF4G1 overexpression is a critical factor in tumor emboli formation and the metastatic nature of IBC (Silvera et al., 2009), reduction in eIF4G1 levels by DSF-Cu in IBC cells (Fig. 3B) and tumors (Fig. 6D) would be expected to reduce tumor aggressiveness. DSF-Cu also inhibited ALDH1 activity, which is linked to cancer stem cells (CSCs) (Croker et al., 2009), enhanced tumorigenic and metastatic potential (Croker et al., 2009), and resistance to chemo- and targeted therapies (Januchowski et al., 2013). Additionally, CSCs exhibit low basal levels of ROS (Diehn et al., 2009), and some studies have shown that ALDH1A1 plays an important role in protection against oxidative stress in stem cells (Singh et al., 2013); thus, ALDH represents an important target for anti-tumor therapy, particularly in redox-adapted cells.

## 5. CONCLUSION

Together, these data reveal the role of DSF as a Cu ionophore and demonstrate anti-cancer efficacy of DSF-Cu in *in vitro* and *in vivo* models of IBC. Additionally, the metagenome analyses of pre-treatment samples supports translation of this FDA-approved drug into clinical trials for advanced breast cancers to enhance and prolong sensitivity to standard chemotherapy.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Ted Huston in the W. M. Keck Lab in the Department of Earth & Environmental Sciences at the University of Michigan for ICP-HRMS analyses, Tao Wang, Hasan Abbas, and Jess Hendin for technical assistance, Drs. Shelley Hwang, P. Kelly Marcom, Dan George, Scott Sauer, and H. Kim Lysterly at Duke for helpful discussions. This work was supported by American Cancer Society Grant RSG-08-290-01-CCE, Dept. of Surgery Research funds and Duke Cancer Institute Cancer and Environment P3917733 sub-award (G. R. Devi), Duke Graduate School Fellowship (J. L. Allensworth), Duke University Diversity Enhancement Fellowship (M. K. Evans), NIH grants GM41840 and DK074192 (D. T. Thiele), CA198818 (D. P. McDonnell.) and NIH Postdoctoral Fellowship F32 GM100678 (R. F. Safi).

## References

Abramoff MD, Magalhaes PJ, Ram SJ. Image Processing with Image. *J Biophotonics International*. 2004; 11:36–42.

- Aird KM, Allensworth JL, Batinic-Haberle I, Lysterly HK, Dewhirst MW, Devi GR. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. *Breast cancer research and treatment*. 2012; 132:109–119. [PubMed: 21559822]
- Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lysterly HK, Devi GR. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. *Molecular cancer therapeutics*. 2008; 7:38–47. [PubMed: 18202008]
- Aird KM, Ghanayem RB, Peplinski S, Lysterly HK, Devi GR. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. *Molecular cancer therapeutics*. 2010; 9:1432–1442. [PubMed: 20406946]
- Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. *Molecular cancer therapeutics*. 2012; 11:1518–1527. [PubMed: 22508521]
- Allensworth JL, Sauer SJ, Lysterly HK, Morse MA, Devi GR. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. *Breast cancer research and treatment*. 2013; 137:359–371. [PubMed: 23225169]
- Bellezza I, Mierla AL, Minelli A. Nrf2 and NF-kappaB and Their Concerted Modulation in Cancer Pathogenesis and Progression. *Cancers*. 2010; 2:483–497. [PubMed: 24281078]
- Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2013
- Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. *Expert opinion on investigational drugs*. 2009; 18:89–97. [PubMed: 19053885]
- Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. *Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer*. *Breast cancer research : BCR*. 2001; 3:323–327. [PubMed: 11597322]
- Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. *Journal of medicinal chemistry*. 2004; 47:6914–6920. [PubMed: 15615540]
- Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2010; 16:45–55. [PubMed: 20028757]
- Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. *Cancer research*. 2006; 66:10425–10433. [PubMed: 17079463]
- Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. *Journal of cellular and molecular medicine*. 2009; 13:2236–2252. [PubMed: 18681906]
- Dawood S, Cristofanilli M. Inflammatory breast cancer: what progress have we made? *Oncology (Williston Park, N Y)*. 2011; 25:264–270. 273.
- Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. *Breast cancer research and treatment*. 2012; 134:495–510. [PubMed: 22547109]
- Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature*. 2009; 458:780–783. [PubMed: 19194462]

- Evans MK, Tovmasyan A, Batinic-Haberle I, Devi GR. Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. *Free radical biology & medicine*. 2013; 68c:302–314. [PubMed: 24334253]
- Faiman MD, Jensen JC, Lacoursiere RB. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. *Clinical pharmacology and therapeutics*. 1984; 36:520–526. [PubMed: 6090051]
- Fraga CG. Relevance, essentiality and toxicity of trace elements in human health. *Molecular aspects of medicine*. 2005; 26:235–244. [PubMed: 16125765]
- Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nature reviews Drug discovery*. 2013; 12:931–947.
- Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. *Cancer treatment reviews*. 2009; 35:32–46. [PubMed: 18774652]
- Hogarth G. Metal-dithiocarbamate complexes: chemistry and biological activity. *Mini reviews in medicinal chemistry*. 2012; 12:1202–1215. [PubMed: 22931592]
- Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. *Breast cancer research and treatment*. 2011; 125:785–795. [PubMed: 21153052]
- Januchowski R, Wojtowicz K, Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2013; 67:669–680. [PubMed: 23721823]
- Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. *Acta psychiatrica Scandinavica Supplementum*. 1992; 369:15–26. [PubMed: 1471547]
- Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2010; 16:4496–4502. [PubMed: 20682709]
- Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. *PLoS one*. 2010; 5:e12180. [PubMed: 20808935]
- Manda G, Nechifor MT, Neagu T-M. Reactive Oxygen Species, Cancer and Anti-Cancer Therapies. *Current Chemical Biology*. 2009; 3:22–46.
- Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2014; 25:384–391. [PubMed: 24351399]
- Mufti AR, Burstein E, Duckett CS. XIAP: cell death regulation s copper homeostasis. *Archives of biochemistry and biophysics*. 2007; 463:168–174. [PubMed: 17382285]
- Mulay IL, Roy R, Knox BE, Suhr NH, Delaney WE. Trace-metal analysis of cancerous and noncancerous human tissues. *Journal of the National Cancer Institute*. 1971; 47:1–13. [PubMed: 4328191]
- Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2006; 12:5047–5054. [PubMed: 16951220]
- Nose Y, Kim BE, Thiele DJ. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. *Cell metabolism*. 2006; 4:235–244. [PubMed: 16950140]

- Pena MM, Koch KA, Thiele DJ. Dynamic regulation of copper uptake and detoxification genes in *Saccharomyces cerevisiae*. *Molecular and cellular biology*. 1998; 18:2514–2523. [PubMed: 9599102]
- Reeder NL, Kaplan J, Xu J, Youngquist RS, Wallace J, Hu P, Juhlin KD, Schwartz JR, Grant RA, Fieno A, Nemeth S, Reichling T, Tiesman JP, Mills T, Steinke M, Wang SL, Saunders CW. Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. *Antimicrobial agents and chemotherapy*. 2011; 55:5753–5760. [PubMed: 21947398]
- Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. *Cancer research*. 1984; 44:5390–5394. [PubMed: 6488192]
- Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. *CA: a cancer journal for clinicians*. 2010; 60:351–375. [PubMed: 20959401]
- Robinson JS, Klionsky DJ, Banta LM, Emr SD. Protein sorting in *Saccharomyces cerevisiae*: isolation of mutants defective in the delivery and processing of multiple vacuolar hydrolases. *Molecular and cellular biology*. 1988; 8:4936–4948. [PubMed: 3062374]
- Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the national cancer database. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2014; 32:2018–2024. [PubMed: 24888808]
- Saigal K, Hurley J, Takita C, Reis IM, Zhao W, Rodgers SE, Wright JL. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. *Clinical breast cancer*. 2013; 13:335–343. [PubMed: 23850216]
- Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. *Nature cell biology*. 2009; 11:903–908.
- Singh S, Brocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A, Thompson DC, Vasiliou V. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. *Free radical biology & medicine*. 2013; 56:89–101. [PubMed: 23195683]
- Taminau J, Meganck S, Lazar C, Steenhoff D, Coletta A, Molter C, Duque R, de Schaetzen V, Weiss Solis DY, Bersini H, Nowe A. Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. *BMC bioinformatics*. 2012; 13:335. [PubMed: 23259851]
- Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nature reviews Drug discovery*. 2009; 8:579–591.
- Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2013; 19:4685–4696. [PubMed: 23396049]
- Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2006; 12:3249–3256. [PubMed: 16740744]
- Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. *International journal of cancer Journal international du cancer*. 2003; 104:504–511. [PubMed: 12584750]
- Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. *Cancer letters*. 2013; 337:77–89. [PubMed: 23689139]



Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL, Wang W. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. *British journal of cancer*. 2011; 104:1564–1574. [PubMed: 21487404]

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript

**HIGHLIGHTS (3-5)**

- A novel, *in vitro* oxidative stress response (OSR) signature is demonstrated
- Using patient samples, we demonstrate that IBC has a higher OSR score than non-IBC
- Redox modulator, disulfiram (DSF)+Cu, induces oxidative stress-mediated apoptosis
- DSF+Cu shows potent anti-tumor efficacy in *in vitro* and *in vivo* IBC models
- Potential for repurposing DSF, an approved anti-alcoholism drug, for IBC therapy



**Figure 1. Oxidative stress response signature in IBC clinical samples**

**A**, Schematic of development of oxidative stress response (OSR) metagene in SUM149 cells, comparing untreated to H<sub>2</sub>O<sub>2</sub> administration. **B**, Expression values of the “oxidative stress response” metagene set generated from H<sub>2</sub>O<sub>2</sub>-treated and untreated SUM149 cells; values are reported as a box plot according to the type of samples (normal breast, IBC, non-IBC). *p*-values are indicated (t-test). **C**, Classification of 389 breast cancer samples from left to right based upon decreasing metagene value; the IBC/non-IBC type is shown above the curve: black for IBC, white for non-IBC. **D**, Heatmap showing expression values in BC samples from **C** for the top 40 genes most differentially expressed. Genes ordered from top to bottom according to decreasing log<sub>2</sub>-ratio. Each row represents a gene and each column a


sample. Expression levels are depicted according to the color scale at the bottom left, and color saturation represents the magnitude of deviation from the median.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




**Figure 2. DSF-Cu reduces cellular antioxidant capacity to induce ROS and activate redox signaling**

SUM149, rSUM149 cells treated with DSF, DSF+Cu (100-300 nM, 10 μM), Cu alone (10 μM). **A**, Fold induction of mitochondrial superoxides (white bars) and percentage of cells with high cytoplasmic superoxides (black bars) measured by flow cytometry. **B**, Immunoblot analysis of SOD1/2. **C**, Reduced glutathione content relative to untreated (rSUM149 shown). **D**, Fold induction of Nrf2 activity measured by ARE-responsive luciferase activity. **E**, Immunoblot analysis of indicated proteins in treated cells at 4 h time point. **F**, Effect of SOD mimetic (MnTnHexyl-2-Pyp<sup>5+</sup>, 100-200 μM) on viability measured by trypan blue exclusion assay (rSUM149 shown). \**p*<0.05, \*\**p*<0.005 in all panels. GAPDH and respective total proteins as loading controls.




**Figure 3. DSF induces Cu-dependent apoptosis**

**A**, Dose-dependent measurement of viability in cells treated with DSF, Cu (10  $\mu$ M), or DSF-Cu. **B**, Immunoblot analysis of apoptotic pathway proteins. GAPDH as loading control. **C**, Viability in the presence of Cu chelators bathocuproine disulphonate (BCS, 100  $\mu$ M, white bars) or tetrathiomolybdate (TM, 10  $\mu$ M, gray bars) measured by trypan blue exclusion assay.



**Figure 4. DSF acts as an ionophore to induce Ctr1-independent Cu uptake**


**A**, Cu content (ng) normalized to protein (mg) in SUM149 (white bars) and rSUM149 (black bars) treated with DSF alone or in combination with Cu measured by ICP-HRMS. \* $p < 0.05$ , \*\* $p < 0.005$ . **B**, Ctr1 expression in normal and IBC cell lines. ←g indicates glycosylated form, ←t indicates truncated form. GAPDH as loading control. **C**, Left: Viability of SUM149 cells treated with Ctr1-targeting siRNAs (black and gray bars) or control luciferase-targeting siRNA (white bars) following DSF (300 nM), Cu (10 μM), or DSF-Cu (100-300 nM, 10 μM) treatment for 24 h. Right: Immunoblot analysis of SUM149 cells treated with Ctr1-targeting siRNAs (A and B) or control luciferase-targeting siRNA. **D**, Growth of SEY6210 and Ctr1/3-deficient MPY17 *S. cerevisiae* cells in YPEG media with addition of ZPT (left) or DSF (right) measured by absorbance at 600nm.



**Figure 5. DSF-Cu inhibits AIG and ALDH activity of IBC cells**

**A**, Representative images of SUM149 mammospheres treated with indicated concentrations. Magnification: 10x, inset: 20x. **B**, Quantification of AIG assay (by colony number) relative to untreated in SUM149 (white bars) and rSUM149 (black bars) cells treated with DSF, Cu (10 μM), or DSF-Cu complex. **C**, Representative AIG images of cells treated as indicated. **D**, Representative dot-plots of ALDH1 activity. Cells were incubated with ALDEFLUOR substrate (BAAA), and the specific inhibitor of ALDH1, DEAB, was used to establish the baseline fluorescence and define ALDEFLUOR-positivity (gated population). DEAB-treated plots are labeled as -ve ctrl. Mean ± SEM of four independent experiments. *Inset*, Labeling of X and Y axes





**Figure 6. DSF-Cu inhibits tumor growth in an *in vivo* model of IBC**

**A**, Tumor volumes (measured  $V = (L \times W^2)/2$ ) of mice with SUM149 subcutaneous flank tumors treated with vehicle, DSF, or DSF-Cu. **B**, Representative immunoblot analysis of indicated proteins in tumor lysates from mice treated with vehicle, DSF, or DSF-Cu. GAPDH as loading control. **C**, Representative images of tumor tissue from mice treated with vehicle, DSF, or DSF-Cu with TUNEL staining. Magnification: 40x. **D**, Quantification of TUNEL positive cells (from **C**). Mean  $\pm$  SEM % TUNEL positive/total number of cells, \* $p < 0.05$ . **E**, Cu content of excised tumors (ng) measured by ICP-HRMS relative to protein (mg). **F**, Schematic representation of DSF-Cu mechanisms of action. DSF-Cu complex acts as a pro-oxidant, induces ROS-mediated cancer cell death by inhibiting NF $\kappa$ B, which attenuates NF $\kappa$ B-dependent antioxidant and anti-apoptotic gene expression. DSF-Cu inhibits ALDH1, which has been implicated in protection from ROS. DSF-Cu also inhibits the

potent anti-apoptotic protein, XIAP, and translation initiation factor eIF4G1 (which can enhance XIAP translation during cell stress), promoting apoptosis.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript